Metabolix Inc. (MBLX) is a biotechnology company focused on the development and commercialization of environmentally sustainable, economically attractive alternatives to petrochemical-based plastics, fuels and chemicals. While we are excited about the prospects of Mirel (Metabolixâs first product), we expect a delay in the companyâs commercialization plans as construction work at the Clinton facility was impacted by a harsh Midwest winter. The construction timing is currently being re-evaluated and we believe that product availability from the Clinton plant is likely to be pushed out to the first quarter of 2009.
Meanwhile, FDA approval for the use of Mirel in food contact applications is yet to come. Food contact applications account for a major part of the companyâs estimated demand (about 64%) for biodegradable plastics in 2010. Metabolix is currently conducting studies and is working on obtaining approval from the FDA.
Though Metabolix is working on other projects, including a second technology platform which is being developed for the co-production of Natural Plastic and biomass feedstock, these programs are still in early stages of development. As such, investor focus is likely to remain on Mirel-related issues in the coming quarters.
The stock has gone down significantly over the past few months - we recommend waiting on the sidelines until we gain more visibility on the ongoing issues related to the Clinton facility and FDA approval for food contact applications. It is difficult to value MBLX shares, given its little revenue and negative EPS. Based on our long-term earnings model, we do not see MBLX posting positive EPS over the next several years.
We rate the shares a Hold with a price target of $12. The stock is currently trading at $11.30 a suitable strategic partnership for the switchgrass program and approval of Mirel for food contact applications could provide upside to the name.
Arpita Dutt, CA, contributed to this report.
Read the full analyst report on MBLX.
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.